Compare Eli Lilly And Co (LLY) vs Trade Desk Inc (TTD) Price & Performance

Eli Lilly And CoTrade

Trade Desk IncTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs Trade Desk Inc — how do they compare? Eli Lilly And Co trades at $1,223.26 (market cap $1.08T), while Trade Desk Inc trades at $13.33 (market cap $6.37B). The key difference: Eli Lilly And Co is far larger — about 169.5× Trade Desk Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while Trade Desk Inc pays none. Which is the better fit depends on your goals.

	LLY	TTD
Market Cap	$1.08T	$6.37B
Sector	Health	Technology
52-Week High	$1.24K	$55.36
52-Week Low	$639.43	$13.39
Enterprise Value	$1.13T	$5.32B
Dividend Yield	0.57%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Trade Desk Inc

The Trade Desk (TTD) stock trades at $13.39, down 2.97% today and near 52-week lows after a sharp 90% decline from its 2024 peak. Recent Q2 2026 earnings missed expectations with 3% revenue growth and weak Q3 guidance, triggering analyst downgrades. Technical indicators are bearish, with support at $12. The company maintains strong profitability margins but faces growth deceleration and competitive pressures in digital advertising.

Outlook remains cautious due to execution gaps and macroeconomic headwinds. While valuations appear reasonable with a P/E of 16.14, near-term risks from revenue declines and advertiser pullbacks outweigh potential upside. Investors should monitor Q3 earnings for signs of stabilization before considering entry.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

LLY

Novo Nordisk CEO says GLP-1 drugs for obesity have huge growth potential and economic benefits aheadFox Business · 4 hours agoBullish Novo Nordisk faces sell rating amid rising competition and operational challenges, with price target cut to $47.Alex Lavoie · 7 hours agoBearish Eli Lilly sues six U.S. entities over illegal black-market retatrutide sales.PRNewsWire · 10 hours agoNeutral View details →

TTD

Court allows thousands of social media addiction lawsuits against Meta and others to proceedForbes · 2 days agoBearish Trade Desk shares drop 5% after Q2 earnings miss and weak guidance, signaling execution issues.24/7 Wall Street · 2 days agoBearish HSBC downgrades The Trade Desk after weak Q2 results and poor Q3 outlook, stock drops 28%.Andrew Wynn · 2 days agoBearish View details →

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

About Trade Desk Inc

The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.